Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) announced plans to acquire three companies for nearly $4 billion, intending to enhance its research efforts in infectious diseases. The acquisition includes Curevo for $1.5 billion, LimmaTech Biologics at $780 million, and Vaccine Company for $1.55 billion. Following this announcement, Eli Lilly's shares increased by 1.3% in premarket trading. The company's strategy emphasizes disease prevention at its source. These moves could impact the company's market position in the growing vaccine sector.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
- Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
- Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
- Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
- Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
